智通财经网·2026-01-20 11:41Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of SHR-9839 and HRS-4642, indicating progress in its oncology drug development pipeline [1] Group 1: SHR-9839 - SHR-9839 is a humanized antibody drug developed by the company, intended for the treatment of advanced solid tumors by blocking two key signaling pathways related to tumor development [1] - The subcutaneous formulation of SHR-9839 has been developed, and there is currently one approved drug targeting the same pathway globally [1] Group 2: HRS-4642 - HRS-4642 is a KRAS G12D inhibitor developed by the company, formulated as a liposome injection [1] - HRS-4642 specifically binds to KRAS G12D and inhibits the phosphorylation of MEK and ERK proteins, demonstrating anti-tumor effects [1] - There are currently no similar drugs approved for HRS-4642 in both domestic and international markets [1]